Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APMNASDAQ:CRDLTSE:GXENYSE:HEXO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$1.09-3.5%$0.95$0.46▼$7.49$6.15M-0.14616,699 shs26,511 shsCRDLCardiol Therapeutics$1.37-4.2%$1.16$0.77▼$2.63$120.67M1.03322,153 shs194,617 shsGXEGear EnergyC$0.50C$0.45▼C$0.80C$126.52M3.52585,822 shs1.03 million shsHEXOHEXO$0.71+2.5%$0.87$0.66▼$3.84$31.24M1.35880,508 shs305,500 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group-3.55%+1.86%+14.47%+12.36%-76.20%CRDLCardiol Therapeutics-4.20%-5.52%+23.42%+16.10%-37.73%GXEGear Energy0.00%0.00%0.00%0.00%-28.36%HEXOHEXO0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPMAptorum Group0.4908 of 5 stars0.03.00.00.00.61.70.6CRDLCardiol Therapeutics1.5878 of 5 stars3.72.00.00.00.60.00.6GXEGear EnergyN/AN/AN/AN/AN/AN/AN/AN/AHEXOHEXON/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPMAptorum Group 0.00N/AN/AN/ACRDLCardiol Therapeutics 3.40Buy$8.67532.60% UpsideGXEGear Energy 2.00HoldN/AN/AHEXOHEXO 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest HEXO, CRDL, APM, and GXE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.004/16/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/7/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPMAptorum Group$430K13.56N/AN/A$2.20 per share0.50CRDLCardiol TherapeuticsN/AN/AN/AN/A$0.22 per shareN/AGXEGear EnergyC$134.93M0.00N/A540.00C$0.93 per share0.00HEXOHEXO$146.20M0.21N/AN/A$2.44 per share0.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPMAptorum Group-$4.27MN/A0.00∞N/AN/AN/AN/A7/30/2025 (Estimated)CRDLCardiol Therapeutics-$26.77M-$0.34N/AN/AN/AN/A-209.63%-141.09%7/14/2025 (Estimated)GXEGear EnergyC$13.02MC$0.0510.39N/AN/A8.53%5.08%4.84%N/AHEXOHEXO-$845.90M-$5.21N/AN/AN/A-235.33%-74.04%-32.51%N/ALatest HEXO, CRDL, APM, and GXE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/31/2025Q4 2024CRDLCardiol Therapeutics-$0.08-$0.07+$0.01-$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPMAptorum GroupN/AN/AN/AN/AN/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/AGXEGear EnergyC$0.0611.46%N/A120.00%N/AHEXOHEXON/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPMAptorum GroupN/A0.220.22CRDLCardiol Therapeutics0.013.263.26GXEGear Energy6.271.200.56HEXOHEXO0.010.410.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPMAptorum Group3.80%CRDLCardiol Therapeutics12.49%GXEGear Energy2.42%HEXOHEXO7.78%Insider OwnershipCompanyInsider OwnershipAPMAptorum Group63.99%CRDLCardiol Therapeutics5.25%GXEGear Energy7.62%HEXOHEXO4.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPMAptorum Group305.35 million1.93 millionNot OptionableCRDLCardiol Therapeutics2082.65 million78.31 millionNot OptionableGXEGear Energy1,310263.58 millionN/ANot OptionableHEXOHEXO1,27744.00 million41.93 millionOptionableHEXO, CRDL, APM, and GXE HeadlinesRecent News About These CompaniesExpert reveals most dangerous garden accessories to watch out for as Britain heats up – causing fires & electric shocksApril 10, 2025 | thesun.ieTilray wins dismissal of $8M shareholder lawsuitMarch 26, 2025 | greenmarketreport.comNEXTG3N series from ARI: Cutting-edge butterfly valves delivering efficiency, durability and customizationNovember 6, 2024 | insights.globalspec.comHexo co-founder Adam Miron launches new advisory firm with former business partnerOctober 29, 2024 | obj.caWarning issued to anyone who uses a heated clothes airer in their homeOctober 24, 2024 | msn.comSCREEN magazine to be unveiled today: Shraddha Kapoor, Rajkumar Hirani and Vijay Varma to lead star-studded relaunchOctober 18, 2024 | financialexpress.comIconic SCREEN magazine to be unveiled today, Shraddha Kapoor to be its first-ever digital coverOctober 18, 2024 | indianexpress.comShraddha Kapoor to unveil SCREEN; will be face of its first digital coverOctober 18, 2024 | indianexpress.comDo you need a cover for your heated airer? It’ll definitely speed up drying - but only if you choose the right kindOctober 12, 2024 | idealhome.co.ukPrevisão de ações da Tilray Brands: níveis a serem observados antes dos lucrosOctober 8, 2024 | msn.comTilray Brands stock forecast: levels to watch ahead of earningsOctober 7, 2024 | invezz.comThe 8 most common fire risks in your home – and how to prevent themOctober 2, 2024 | msn.comA 614-Square-Foot Art Nouveau Apartment in France Gets a Bold UpdateSeptember 30, 2024 | architecturaldigest.comElectric blanket users must do these five things as temperatures plummetSeptember 29, 2024 | express.co.ukTech30: most promising Indian startups of 2024September 27, 2024 | yourstory.comMedical Marijuana Market to Grow by USD 39.8 Billion (2024-2028), Driven by Product Launches, How AI is Shaping the Market - Technavio ReportSeptember 9, 2024 | finance.yahoo.comIs Hexo Corp (HEXO) Stock a Good Investment?September 4, 2024 | aaii.comTwo cannabis stocks analysts love right nowAugust 28, 2024 | cantechletter.comVillage Farms is “incredibly undervalued”, Beacon saysAugust 21, 2024 | cantechletter.comTilray to Acquire Craft Beer Brands from Molson CoorsAugust 13, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHEXO, CRDL, APM, and GXE Company DescriptionsAptorum Group NASDAQ:APM$1.09 -0.04 (-3.55%) Closing price 06/17/2025 03:54 PM EasternExtended Trading$1.02 -0.07 (-6.32%) As of 06:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.Cardiol Therapeutics NASDAQ:CRDL$1.37 -0.06 (-4.20%) Closing price 06/17/2025 04:00 PM EasternExtended Trading$1.37 0.00 (0.00%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Gear Energy TSE:GXEGear Energy Ltd., an exploration and production company, engages in the acquiring, developing, and holding of interests in petroleum and natural gas properties and assets in Canada. The company's oil properties are located in Central Alberta, West Central Saskatchewan, and Southeast Saskatchewan. Gear Energy Ltd. is headquartered in Calgary, Canada.HEXO NYSE:HEXOHEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada. As of June 22, 2023, HEXO Corp. operates as a subsidiary of Tilray Brands, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Downgrades Joby, But Overlooks Major Regulatory Wins Applied Digital: Now the High-Stakes Race to Build Begins Zscaler Upgraded: Wall Street Forecasts 26% More Upside U.S. Steel Stock Burns the Bears With Surprise Upside Move Is CrowdStrike Stock Set to Break Out or Cool Off? Can Luckin and Dutch Bros Take Market Share From Starbucks? New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
